These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37989709)

  • 61. Association between the Absolute Baseline Lymphocyte Count and Response to Neoadjuvant Platinum-based Chemotherapy in Muscle-invasive Bladder Cancer.
    Leibowitz-Amit R; Israel A; Gal M; Atenafu EA; Symon Z; Portnoy O; Laufer M; Dotan Z; Ramon J; Avni D; Fridman E; Berger R
    Clin Oncol (R Coll Radiol); 2016 Dec; 28(12):790-796. PubMed ID: 27498850
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cystectomy vs. bladder preservation after neoadjuvant chemotherapy in muscle-invasive bladder cancer: A tertiary medical center experience.
    Halabi IE; Husseini ZE; Haibe Y; Charafeddine M; Mukherji D; Temraz S; Bulbul M; Khauli R; Nasr R; Wazzan W; Hajj AE; Geara F; Shamseddine A
    Cancer Treat Res Commun; 2020; 25():100222. PubMed ID: 33080450
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Molecular subtypes applied to a population-based modern cystectomy series do not predict cancer-specific survival.
    Kollberg P; Chebil G; Eriksson P; Sjödahl G; Liedberg F
    Urol Oncol; 2019 Oct; 37(10):791-799. PubMed ID: 31056435
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Comparing Pathologic and Survival Outcomes Between Primary and Secondary Muscle Invasive Bladder Cancer When Treated by Radical Cystectomy With or Without Neoadjuvant Chemotherapy.
    Benidir T; Lone Z; Zhang A; Nowacki AS; Munoz-Lopez C; Hegde P; Fung K; Fajnzylber J; Abouassaly R; Berglund R; Klein EA; Eltemamy M; Kaouk J; Weight CJ; Almassi N; Pascal-Haber G; Lee BH
    Urology; 2022 Oct; 168():137-142. PubMed ID: 35772481
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Natural History and Genomic Landscape of Chemotherapy-Resistant Muscle-Invasive Bladder Cancer.
    Lenis AT; Whiting K; Ravichandran V; Tallman JE; Alam SM; Chu CE; Jesus Escano M; Bochner E; Katims A; Reisz PA; Truong H; Clinton TN; Telis L; Dason S; McPherson V; Teo MY; Funt S; Aggen D; Goh AC; Donahue TF; Cha EK; Donat SM; Herr HW; Dalbagni G; Schultz N; Berger MF; Bajorin DF; Rosenberg JE; Bochner BH; Ostrovnaya I; Al-Ahmadie H; Solit DB; Iyer G; Pietzak EJ
    JCO Precis Oncol; 2024 Apr; 8():e2300274. PubMed ID: 38691813
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Use of Neoadjuvant Chemotherapy in Elderly Patients With Muscle-Invasive Bladder Cancer: A Population-Based Study, 2006-2017.
    Posielski N; Koenig H; Ho O; Porter C; Flores JP
    Oncology (Williston Park); 2022 Jan; 36(1):21-33. PubMed ID: 35089670
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Impact of Lymphovascular Invasion on Prognosis in the Patients with Bladder Cancer-Comparison of Transurethral Resection and Radical Cystectomy.
    Yoneda K; Kamiya N; Utsumi T; Wakai K; Oka R; Endo T; Yano M; Hiruta N; Ichikawa T; Suzuki H
    Diagnostics (Basel); 2021 Feb; 11(2):. PubMed ID: 33557407
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens.
    Kunju LP; You L; Zhang Y; Daignault S; Montie JE; Lee CT
    J Urol; 2008 Nov; 180(5):1928-32; discussion 1932. PubMed ID: 18801529
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Fahmy O; Khairul-Asri MG; Schubert T; Renninger M; Malek R; Kübler H; Stenzl A; Gakis G
    Urol Oncol; 2018 Feb; 36(2):43-53. PubMed ID: 29102254
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens.
    Mari A; Kimura S; Foerster B; Abufaraj M; D'Andrea D; Hassler M; Minervini A; Rouprêt M; Babjuk M; Shariat SF
    BJU Int; 2019 Jan; 123(1):11-21. PubMed ID: 29807387
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A population-based retrospective analysis on variation in use of neoadjuvant chemotherapy depending on comorbidity in patients with muscle-invasive bladder cancer undergoing cystectomy in Denmark in the period 2013-2019.
    Körner SK; Jensen JB
    Scand J Urol; 2022 Feb; 56(1):34-38. PubMed ID: 34775886
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Residual CIS after neoadjuvant chemotherapy and radical cystectomy for muscle invasive bladder cancer: Implications for neoadjuvant trials.
    Gabrielson AT; Daniels MJ; Rowe J; Alam R; Lee EJ; Matoso A; De Felice A; Hahn N; Hoffman-Censits J; Bivalacqua TJ; Kates M
    Urol Oncol; 2022 Apr; 40(4):164.e9-164.e16. PubMed ID: 35045949
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Modelling cost-effectiveness of a biomarker-based approach to neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Lotan Y; Woldu SL; Sanli O; Black P; Milowsky MI
    BJU Int; 2018 Sep; 122(3):434-440. PubMed ID: 29603871
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA.
    Hanna N; Trinh QD; Seisen T; Vetterlein MW; Sammon J; Preston MA; Lipsitz SR; Bellmunt J; Menon M; Choueiri TK; Abdollah F
    Eur Urol Oncol; 2018 May; 1(1):83-90. PubMed ID: 31100232
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
    Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
    Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis.
    Soria F; Black PC; Fairey AS; Cookson MS; Yu EY; Kassouf W; Dall'Era MA; Sridhar SS; McGrath JS; Wright JL; Thorpe AC; Morgan TM; Daneshmand S; Holzbeierlein JM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Grivas P; Stephenson AJ; Shah JB; van Rhijn BW; Spiess PE; Shariat SF; Gontero P
    BJU Int; 2021 Jul; 128(1):79-87. PubMed ID: 33152179
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Neoadjuvant chemotherapy for muscle invasive bladder cancer: a nationwide investigation on survival.
    Russell B; Sherif A; Häggström C; Josephs D; Kumar P; Malmström PU; Van Hemelrijck M
    Scand J Urol; 2019 Aug; 53(4):206-212. PubMed ID: 31174452
    [No Abstract]   [Full Text] [Related]  

  • 78. Prediction of cancer-specific survival after radical cystectomy in pT4a urothelial carcinoma of the bladder: development of a tool for clinical decision-making.
    Aziz A; Shariat SF; Roghmann F; Brookman-May S; Stief CG; Rink M; Chun FK; Fisch M; Novotny V; Froehner M; Wirth MP; Schnabel MJ; Fritsche HM; Burger M; Pycha A; Brisuda A; Babjuk M; Vallo S; Haferkamp A; Roigas J; Noldus J; Stredele R; Volkmer B; Bastian PJ; Xylinas E; May M
    BJU Int; 2016 Feb; 117(2):272-9. PubMed ID: 25381844
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle-Invasive Bladder Cancer: Elective and Eligibility Factors Impacting Utilization.
    Patel HD; Naha U; Chen VS; Ko C; Yang R; Druck A; Rac G; Ellis JL; Gupta GN; Woods ME; Gorbonos A; Flanigan R; Quek ML
    Urol Pract; 2024 Jan; 11(1):136-144. PubMed ID: 37913791
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The Prognostic Value of Tumor Regression Grades Combined With TNM Classification in Patients With Muscle-Invasive Bladder Cancer Who Underwent Neoadjuvant Chemotherapy Followed by Radical Cystectomy.
    Gronostaj K; Czech AK; Fronczek J; Drobniak A; Okon K; Chlosta PL; Szczeklik W
    Clin Genitourin Cancer; 2019 Dec; 17(6):e1203-e1211. PubMed ID: 31588010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.